Free Trial

Rafferty Asset Management LLC Has $4.98 Million Position in Vaxcyte, Inc. $PCVX

Vaxcyte logo with Medical background

Key Points

  • Rafferty Asset Management LLC reduced its holdings in Vaxcyte, Inc. by 10.6%, now owning 131,812 shares worth approximately $4.98 million.
  • Vaxcyte reported a loss of ($1.22) earnings per share for the recent quarter, missing expectations and indicating a need for improvement in financial performance.
  • The consensus rating for Vaxcyte among analysts is "Buy", with a target price of $136.50, suggesting potential for future gains despite recent losses.
  • MarketBeat previews the top five stocks to own by October 1st.

Rafferty Asset Management LLC cut its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 131,812 shares of the company's stock after selling 15,624 shares during the period. Rafferty Asset Management LLC owned 0.10% of Vaxcyte worth $4,977,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PCVX. AlphaQuest LLC acquired a new position in shares of Vaxcyte during the first quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Vaxcyte in the first quarter valued at approximately $35,000. Parallel Advisors LLC lifted its holdings in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after buying an additional 1,071 shares during the period. IFP Advisors Inc lifted its holdings in Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after buying an additional 1,306 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after buying an additional 293 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $130.00.

View Our Latest Analysis on PCVX

Vaxcyte Trading Down 0.3%

Shares of PCVX stock traded down $0.10 during trading hours on Wednesday, hitting $31.47. 295,624 shares of the company were exchanged, compared to its average volume of 1,756,342. The company has a market capitalization of $4.08 billion, a PE ratio of -7.65 and a beta of 1.04. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The business has a 50 day moving average of $33.24 and a two-hundred day moving average of $41.73.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter last year, the company earned ($1.10) EPS. On average, research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Read More

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Should You Invest $1,000 in Vaxcyte Right Now?

Before you consider Vaxcyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.

While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.